Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
Market Drivers & Limiters for each chapter segment
Competitive Analysis for each chapter segment
Section on recent mergers & acquisitions
Growth in unit sales will be very stable over the forecast period. “A Randomized Trial of Unruptured Brain Arteriovenous Malformations” (ARUBA) compared interventional and conservative treatment of arteriovenous malformations in the brain and found that conservative management with medication was more effective than embolization. However, some experts have expressed concerns regarding the clinical conclusions of the study due to relatively short follow-up and difficulties with patient recruitment. Therefore even due the market limiter imposed by the trial results, unit sales have continues to grow steadily in line with procedural growth. Approximately two to three units of liquid embolics are needed on average for procedures.
The ASP is also expected to remain stable as there is only one competitor in the market. There may be others that enter the market over the forecast period but this technology has held a monopoly on this market for many years now.
Embolization is a non-surgical, minimally invasive procedure that involves the selective occlusion of blood vessels by purposely introducing emboli. The procedure is a minimally invasive alternative to open surgery and is performed by interventional radiologists and interventional neuroradiologists. Liquid embolic products are used for the embolization of both aneurysms (weakened balloon-like portions of a vessel) and arterio-venous malformations (AVMs).